Clinical trials: Recurrent GBM
Malignant Glioma
Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma
The purpose of this study is to assess the activity of Sym004, a recombinant antibody mixture that specifically binds to EGFR, in patients diagnosed with recurrent glioblastoma whose tumor is EGFR amplified.
- Trial name
- NCT02540161
- Testing
- Sym004 - 18 mg/kg, Sym004 - 24 mg/kg
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Annick Desjardins
Recurrent Glioblastoma
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
- Trial name
- NCT05638451
- Testing
- Sintilimab plus Bevacizumab and Temozolomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Glioblastoma, Anaplastic Astrocytoma
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Primary brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Glioma
- Trial name
- NCT02800486
- Testing
- Intra-arterial Cetuximab, Intra-arterial Mannitol, Hypofractionated re-irradiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Northwell Health
Malignant Glioma, Glioblastoma Multiforme
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00683761
- Testing
- 131I-TM601
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- TransMolecular
Malignant Glioma
MK-2206 for Recurrent Malignant Glioma
MK-2206 is a newly discovered drug that may slow or stop cancer growth. This drug has been used in other research studies, and information from those other research studies suggests that MK-2206 may help to slow or stop the…
- Trial name
- NCT01249105
- Testing
- MK-2206
- Where
- 5 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancers, Lymphoma
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab.
- Trial name
- NCT01983969
- Testing
- Azacitidine, Vorinostat, Gemcitabine
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Glioma, Recurrent Glioblastoma
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
The main purpose of this trial is to investigate the effects of a new class of drugs that help the patient's immune system attack their tumor (glioblastoma multiforme - GBM).
- Trial name
- NCT02794883
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Surgical Procedure
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
High Grade Glioma
Nimotuzumab in Children With HGG
Determination of efficiency of nimotuzumab in children with high grade glioma.
- Trial name
- NCT00561873
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Oncoscience AG
Glioblastoma, Gliosarcoma
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354913
- Testing
- hydroxyurea, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma, Malignant Glioma
CARv3-TEAM-E T Cells in Glioblastoma
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma.
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Trial name
- NCT05660369
- Testing
- CARv3-TEAM-E T cells
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marcela V. Maus, M.D.,Ph.D.
Glioblastoma, Gliosarcoma
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma
Primary Objective To determine maximum tolerated dose \& dose limiting toxicity of Zactima when combined w standard dosing of imatinib mesylate \& hydroxyurea among pts w recurrent malignant glioma who are on \& not on…
- Trial name
- NCT00613054
- Testing
- Zactima, Gleevec, Hydroxyurea
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Annick Desjardins
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
Cilengitide may stop the growth of glioblastoma multiforme by blocking blood flow to the tumor. Giving cilengitide before and after surgery may be an effective treatment for glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00112866
- Testing
- cilengitide, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
GBM
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
This is a multicenter, randomized, controlled study, aiming to evaluate the efficacy and safety of CAN008 administered once-weekly with rRT for treating first tumor recurrence in patients with GBM.
- Trial name
- NCT03746288
- Testing
- CAN008
- Volunteers
- 60 people
- Sponsor
- CANbridge Life Sciences Ltd.
Brain and Central Nervous System Tumors
Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide and carmustine, work in different ways to stop tumor cells from dividing…
- Trial name
- NCT00086879
- Testing
- carmustine, erlotinib hydrochloride, temozolomide
- Where
- 10 sites in Belgium, France and 3 more
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain Tumor, Glioblastoma
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
The purpose of this study is to evaluate the safety and tolerability of oral Dichloroacetate (DCA) in the treatment of recurrent malignant brain tumors (RMBTs).
- Trial name
- NCT01111097
- Testing
- Dichloroacetate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Florida
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma
- Trial name
- NCT01250470
- Testing
- Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Glioblastoma Multiforme, Relapse
Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide.
- Trial name
- NCT06356883
- Testing
- IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Université de Sherbrooke
Brain and Central Nervous System Tumors
Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors
RATIONALE: Inserting the gene for p53 into a person's brain cells may improve the body's ability to fight cancer. PURPOSE: Phase I trial to study the effectiveness of p53 gene therapy with SCH-58500 in treating patients who have…
- Trial name
- NCT00004080
- Testing
- recombinant adenovirus-p53 SCH-58500, conventional surgery
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme
Clinical Part: The objective of this study is to determine the efficacy and safety of SUTENT in patients with recurrent or progressive glioblastoma multiforme.Patients with tissue based diagnosis of intracranial glioblastoma…
- Trial name
- SURGE01-07 (NCT00535379)
- Testing
- Sunitinib
- Where
- 10 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- Medical University Innsbruck